Interius BioTherapeutics Secures $82.5 Million in Series B Funding for Breakthrough Cell and Gene Therapy Delivery Technology

Interius BioTherapeutics, an innovative early-stage biotechnology company at the forefront of advancing cell and gene therapy, has successfully raised an impressive $82,500,000 in its latest funding round. This significant capital infusion will play a pivotal role in propelling the company’s mission to revolutionize therapeutic delivery mechanisms. Founded on groundbreaking inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania, Interius is focused on developing next-generation delivery technologies that aim to enhance the efficacy and accessibility of cell and gene therapies. The funds will be strategically allocated toward accelerating the research and development of these transformative delivery technologies, enabling the company to unlock new treatment possibilities for a range of genetic disorders and chronic illnesses. Furthermore, this investment will bolster Interius’ ability to scale operations and foster strategic partnerships within the biotech ecosystem, ultimately laying the groundwork for clinical trials and regulatory advancements. The team at Interius is committed to leveraging this financial support to not only advance their proprietary platform but also to contribute positively to the growing field of regenerative medicine, where the promise of cell and gene therapy can be realized. As the company charts its course forward, this funding represents a watershed moment in driving forward innovative solutions that could reshape the future of patient care. With a dedicated focus on scientific excellence and patient outcomes, Interius BioTherapeutics is well-positioned to make significant strides in the biotech landscape.